Get the Stockscreener App
2.00
12.36%
0.22
After Hours:
2.05
0.05
+2.50%
Protalix BioTherapeutics Inc. stock is traded at $2.00, with a volume of 3.80M.
It is up +12.36% in the last 24 hours and up +14.94% over the past month.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.
See More
Previous Close:
$1.78
Open:
$1.78
24h Volume:
3.80M
Relative Volume:
4.89
Market Cap:
$160.84M
Revenue:
$63.63M
Net Income/Loss:
$10.62M
P/E Ratio:
40.00
EPS:
0.05
Net Cash Flow:
$-8.64M
1W Performance:
+11.11%
1M Performance:
+14.94%
6M Performance:
+35.14%
1Y Performance:
-11.89%
1-Day Range:
$1.78
$2.06
1-Week Range:
$1.72
$2.06
52-Week Range:
$1.32
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Name
Protalix BioTherapeutics Inc.
Sector
Industry
Phone
972 4 988 9488
Address
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.00 | 143.15M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-08-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-17-17 | Reiterated | Rodman & Renshaw | Buy |
| Apr-04-16 | Initiated | Rodman & Renshaw | Buy |
| Apr-23-15 | Upgrade | Jefferies | Hold → Buy |
| Nov-12-14 | Reiterated | R. F. Lafferty | Buy |
| Jan-24-14 | Initiated | R. F. Lafferty | Buy |
| May-02-12 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-02-12 | Reiterated | Oppenheimer | Outperform |
| Apr-30-12 | Downgrade | Auriga | Buy → Hold |
| Oct-13-11 | Initiated | Morgan Joseph | Hold |
| Mar-17-11 | Downgrade | WBB Securities | Strong Buy → Buy |
| Nov-09-10 | Reiterated | Oppenheimer | Outperform |
| Oct-14-10 | Reiterated | UBS | Buy |
| Dec-02-09 | Reiterated | Hapoalim | Outperform |
| Sep-22-09 | Initiated | Canaccord Adams | Buy |
| Sep-02-09 | Initiated | Hapoalim | Outperform |
| Dec-01-08 | Reiterated | Oppenheimer | Outperform |
| Mar-11-08 | Initiated | UBS | Buy |
| Nov-20-07 | Initiated | CIBC Wrld Mkts | Sector Outperform |
View All
Protalix BioTherapeutics Inc. Stock (PLX) Latest News
Is Protalix BioTherapeutics Inc. (PBDA) stock a safe buy pre earningsJuly 2025 Short Interest & Fast Moving Trade Plans - ulpravda.ru
Is Protalix BioTherapeutics Inc. (DE) stock dividend growth reliablePortfolio Value Summary & Risk Controlled Stock Alerts - ulpravda.ru
Will Protalix BioTherapeutics Inc. stock gain from strong economyNew Guidance & AI Forecasted Entry and Exit Points - ulpravda.ru
Will Protalix BioTherapeutics Inc. (PBDA) stock sustain dividend payoutsPortfolio Value Report & Daily Chart Pattern Signal Reports - ulpravda.ru
Is Protalix BioTherapeutics Inc. (PBDA) stock among top earnings playsWeekly Investment Report & Stepwise Trade Signal Implementation - ulpravda.ru
Can Protalix BioTherapeutics Inc. stock hit analyst price targetsProfit Target & Long-Term Safe Investment Plans - ulpravda.ru
What technical charts say about Protalix BioTherapeutics Inc. stock2025 Support & Resistance & Risk Managed Investment Signals - ulpravda.ru
Will Protalix BioTherapeutics Inc. (PBDA) stock outperform Dow JonesEconomic Indicators Overview & Free Expert Stock Watchlists - ulpravda.ru
Why Protalix BioTherapeutics Inc. (DE) stock benefits from AI revolution2026 world cup usa national team qualification young talents pressing system expert forecast preview - ulpravda.ru
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy By Investing.com - Investing.com Nigeria
Protalix BioTherapeutics CEO outlines 2026 priorities, highlights progress across clinical pipeline - Proactive financial news
Protalix outlines 2026 strategy with focus on uncontrolled gout therapy - Investing.com
Protalix BioTherapeutics, Inc. Provides 2026 Strategic Update - TradingView — Track All Markets
Protalix BioTherapeutics Letter to Stockholders - Nasdaq
What’s Driving Mazda Limited Stock’s Recent Momentum Key TrendsSector Performance Drivers & Explosive Profit Growth - earlytimes.in
Market Fear: How strong is Protalix BioTherapeutics Inc DE stock earnings growthWeekly Trade Recap & Community Trade Idea Sharing - moha.gov.vn
Protalix BioTherapeutics (AMEX: PLX)Related Research - intelligentinvestor.com.au
Protalix BioTherapeutics (NYSE:PLX) CEO Buys $101,360.00 in Stock - MarketBeat
Bashan Dror, Protalix BioTherapeutics CEO, buys $101k in shares By Investing.com - Investing.com Canada
Protalix BioTherapeutics (PLX) CEO and director reports 56,000-share stock purchase - Stock Titan
PLX: Secarna's Antisense Oligonucleotide Discovery Collaboration - Research Tree
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration - Zacks Small Cap Research
How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Opening Moves & Community Verified Trade Alerts - Улправда
Why Protalix BioTherapeutics Inc. (DE) stock remains stableJuly 2025 Levels & Daily Momentum Trading Reports - ulpravda.ru
Will Protalix BioTherapeutics Inc. (DE) stock outperform Dow JonesWeekly Gains Summary & Entry Point Strategy Guides - DonanımHaber
Can Protalix BioTherapeutics Inc. stock beat analyst upgradesWeekly Gains Summary & Verified Entry Point Detection - Улправда
Institution Moves: Is Protalix BioTherapeutics Inc. stock a contrarian buyBond Market & Community Verified Trade Signals - Улправда
Is Protalix BioTherapeutics Inc. (DE) stock a buy before new product rolloutJuly 2025 Institutional & Reliable Price Breakout Alerts - DonanımHaber
Sentiment Review: Is Protalix BioTherapeutics Inc. stock attractive for hedge fundsJuly 2025 Volume & High Win Rate Trade Tips - Улправда
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3%Still a Buy? - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Trading Up 2.3% – Still a Buy? - Defense World
Protalix, Secarna in agreement to develop rare kidney disorder therapies - MSN
Breakout Zone: How Protalix BioTherapeutics Inc. (DE) stock reacts to weak economyJuly 2025 Technicals & AI Forecast for Swing Trade Picks - Улправда
Is Protalix BioTherapeutics Inc. stock a contrarian buy2025 Big Picture & Technical Pattern Based Buy Signals - Улправда
Protalix and Secarna partner to develop rare kidney disease treatments By Investing.com - Investing.com South Africa
Protalix BioTherapeutics partners with Secarna Pharmaceuticals on rare kidney disease drug development - Proactive financial news
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement - Finviz
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Protalix BioTherapeutics (PLX) Partners with Secarna for Kidney Disorder Treatments - GuruFocus
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter Into Collaboration and Option Agreement - 富途牛牛
Protalix Partners With Secarna to Jointly Develop Therapies for Rare Renal Indications - marketscreener.com
Protalix and Secarna partner to develop rare kidney disease treatments - Investing.com
Protalix Biotherapeutics and Secarna Pharmaceuticals enter into collaboration and option agreement - marketscreener.com
Protalix BioTherapeutics Earnings Notes - Trefis
Protalix BioTherapeutics (PLX) Price Target Decreased by 10.71% to 12.75 - Nasdaq
Why analysts recommend Protalix BioTherapeutics Inc. (PBDA) stockJuly 2025 Selloffs & Detailed Earnings Play Strategies - Newser
Will Protalix BioTherapeutics Inc. (PBDA) stock rise with strong economy2025 Analyst Calls & Capital Protection Trading Alerts - Newser
How Protalix BioTherapeutics Inc. (DE) stock performs in volatility spikes2025 Short Interest & Growth Oriented Trading Recommendations - Newser
Why global investors buy Protalix BioTherapeutics Inc. (DE) stockMarket Sentiment Summary & Technical Entry and Exit Tips - Newser
Is Protalix BioTherapeutics Inc. (PBDA) stock a contrarian opportunity - Newser
Will Protalix BioTherapeutics Inc. (DE) stock split increase liquidityJuly 2025 Snapshot & Low Drawdown Momentum Trade Ideas - Newser
Protalix BioTherapeutics Inc. Stock (PLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):